Compare DCBO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | IMMX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.8M | 528.0M |
| IPO Year | 2020 | 2021 |
| Metric | DCBO | IMMX |
|---|---|---|
| Price | $17.21 | $9.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.00 | $19.20 |
| AVG Volume (30 Days) | 230.0K | ★ 683.9K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.89 | N/A |
| Revenue Next Year | $11.44 | N/A |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $1.87 |
| 52 Week High | $33.42 | $11.61 |
| Indicator | DCBO | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 43.88 |
| Support Level | $16.28 | $8.15 |
| Resistance Level | $19.96 | $10.53 |
| Average True Range (ATR) | 1.26 | 0.73 |
| MACD | -0.36 | -0.04 |
| Stochastic Oscillator | 21.29 | 27.33 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.